Yahoo
NasdaqGM - Delayed Quote USD

Evolus, Inc. (EOLS)

9.30 +0.25 (+2.76%)
At close: September 4 at 4:00:01 PM EDT
9.18 -0.12 (-1.29%)
After hours: September 4 at 7:30:04 PM EDT
Trade EOLS on Coinbase
Chart Range Bar
Loading chart for EOLS
Chart does not reflect overnight price.
  • Previous Close 9.05
  • Open 9.05
  • Bid 4.47 x 200
  • Ask 7.82 x 200
  • Day's Range 8.98 - 9.31
  • 52 Week Range 3.86 - 9.31
  • Volume 696,364
  • Avg. Volume 895,114
  • Market Cap (intraday) 614.269M
  • Beta (5Y Monthly) 1.43
  • PE Ratio (TTM) --
  • EPS (TTM) -0.53
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 15.00

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

www.evolus.com

353

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

EOLS
39.85%
S&P 500 (^GSPC)
12.75%

1-Year Return

EOLS
23.83%
S&P 500 (^GSPC)
18.71%

3-Year Return

EOLS
6.16%
S&P 500 (^GSPC)
70.93%

5-Year Return

EOLS
3.33%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 84.08M
Earnings -8.05M
Profit Margin -9.58%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
20M
40M
60M
80M
-20.0%
-15.0%
-10.0%
-5.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

12.00
15.00 Average
9.30 Current
20.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/25/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 13 -> 13

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -10.85%

  • Return on Assets (ttm)

    -5.68%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    316.49M

  • Net Income Avi to Common (ttm)

    -34.33M

  • Diluted EPS (ttm)

    -0.53

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    45.17M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.82M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: